Black Canyon Bio

Biotechnology Research • • 1-10 Employees

Company overview

Headquarters	XX
Website	blackcanyonbio.com
NAICS	541714
Employees	1-10

Key Contact at Black Canyon Bio

Alexis Weston

Director Of Strategic Development

Black Canyon Bio Email Formats

Black Canyon Bio uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@blackcanyonbio.com), used 100% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@blackcanyonbio.com	100%

About Black Canyon Bio

Black Canyon Bio (BCB) is developing novel products for treating cancer using our proprietary Specific Neo-Antigen Peptides (SNAP) Technology platform. SNAP Technology has product development applications across many cancers and other diseases. SNAP Technology was developed by Dr. Sunil Sharma and his team at the Translational Genomics Research Institute (TGen), part of the City of Hope Medical Network, where Dr. Sharma is a Deputy Director of Clinical Sciences and Professor and Division Director of Applied Cancer Research and Drug Discovery, and directs the City of Hope Center for Cancer Prevention and Early Detection. BCB’s first two products, SNAP-Vac (a personalized cancer vaccine) and SNAP-TIL (a personalized cellular therapy) will start human clinical testing in 2024. The market for cancer vaccines and cellular therapies is expected to grow exponentially during the next decade, and these SNAP-based cancer treatments have the potential to be leading products.

Black Canyon Bio revenue & valuation

Annual revenue	$513,330
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,700,000
Total funding	No funding